A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.
Antineoplastic Agents
/ adverse effects
Cancer Vaccines
/ adverse effects
Clinical Trials as Topic
Cytotoxins
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ classification
Female
Humans
Immunologic Factors
/ adverse effects
Long Term Adverse Effects
/ chemically induced
Male
Middle Aged
Molecular Targeted Therapy
/ adverse effects
Neoplasms
/ drug therapy
Prevalence
Severity of Illness Index
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
10
12
2018
accepted:
25
02
2019
pubmed:
31
3
2019
medline:
14
5
2020
entrez:
31
3
2019
Statut:
ppublish
Résumé
Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointestinal disorders, skin and subcutaneous tissue disorders, and cardiac disorders, and compared their longitudinal toxicity data among four types of cancer therapeutics. In total, 28,235 patients who were enrolled into 772 early-phase trials to evaluate the monotherapies of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, or cancer vaccines were evaluated. For each toxicity, we compared their grade prevalence, mean grade at each cycle, and time to toxicity occurrence and identified the potential underlying similarities and differences of longitudinal toxicities among the four cancer treatment types. Our results will further help in understanding the profile of cancer therapeutic toxicities and their impact on oncology treatment in practice.
Substances chimiques
Antineoplastic Agents
0
Cancer Vaccines
0
Cytotoxins
0
Immunologic Factors
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-809Informations de copyright
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.
Références
Ratain, M.J., Lawrence, T.S., Runowicz, C., Turner, S., Wade III, J.L. Critical role of phase 1 clinical trials in cancer treatment. J. Clin. Oncol. 15, 853-859 (1997).
Crowley, J. & Hoering, A. Handbook of Statistics in Clinical Oncology, 3rd edn (CRC Press, New York, NY, 2017).
Ratain, M.J. & Stadler, W.M. Clinical trial designs for cytostatic agents. J. Clin. Oncol. 19, 3154-3155 (2001).
Rahma, O.E., Gammoh, E., Simon, R.M. & Khleif, S.N. Is the “3 + 3” dose escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin. Cancer Res. 20, 4758-4767 (2014).
Jänne, P.A., Kim, G., Shaw, A.T., Sridhara, R., Pazdur, R. & McKee, A.E. Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle. Clin. Cancer Res. 22, 2613-2617 (2016).
Nie, L. et al. Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin. Cancer Res. 22, 2623-2629 (2016).
Hirakawa, A., Sato, H., Daimon, T. & Matsui, S. Modern Dose-finding Designs for cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents (Springer, Tokyo, Japan, 2018).
Le Tourneau, C., Diéras, V., Tresca, P., Cacheux, W. & Paoletti, X. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol. 5, 65-72 (2010).
Le Tourneau, C. et al. Heterogeneity in the definition of dose-limiting toxicity in phase 1 cancer clinical trials of molecularly targeted agents: a review of the literature. Eur. J. Cancer 47, 1468-1475 (2011).
Penel, N., Adenis, A., Clisant, S. & Bonneterre, J. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. Invest. New Drugs 29, 1414-1419 (2011).
Postel-Vinay, S. et al. Phase 1 trials of molecularly targeted agents: should we pay more attention to late toxicities? J. Clin. Oncol. 29, 1728-1735 (2011).
Postel-Vinay, S. et al. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents - Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. Eur. J. Cancer 50, 2040-2049 (2014).
Drilon, A. et al. Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer 122, 1228-1237 (2016).
Dorris, K. et al. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatr. Blood Cancer 64, e26258 (2017).
Jordan, E.J., Spicer, J. & Sarker, D. Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents. Oncotarget 9, 33961-33971 (2018).
Hirakawa, A. et al. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 109, 207-214 (2018).
Boone, S.L., Rademaker, A., Liu, D., Pfeiffer, C., Mauro, D.J. & Lacouture, M.E. Impact and management of skin toxicity associated with antiepidermal growth factor receptor therapy: survey results. Oncology 72, 152-159 (2007).
Ewer, S.M. & Ewer, M.S. Cardiotoxicity profile of trastuzumab. Drug Saf. 31, 459-467 (2008).
Volkova, M. & Russell, R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 7, 214-220 (2011).
Moslehi, J.J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457-1467 (2016).
McGowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M. & Yello, D.M. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc. Drugs Ther. 31, 63-75 (2017).
Kummar, S., Gutierrez, M., Doroshow, J.H. & Murgo, A.J. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br. J. Clin. Pharmacol. 62, 15-26 (2006).
Boussios, S., Pentheroudakis, G., Katsanos, K. & Pavlidisa, N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 25, 106-118 (2012).
Giavridis, T., van der Stegen, S.J.C., Eyquem, J., Hamieh, M., Piersigilli, A. & Sadelain, M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731-738 (2018).
Thanarajasingam, G., Atherton, P.J., Novotny, P.J., Loprinzi, C.L., Sloan, J.A. & Grothey, A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 17, 663-670 (2016).
Weber, J.S., Yang, J.C., Atkins, M.B. & Disis, M.L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092-2099 (2015).
Xu, C. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 8, 363 (2018).
El Osta, B., Hu, F., Sadek, R., Chintalapally, R. & Tang, S.C. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit. Rev. Oncol. Hematol. 119, 1-12 (2017).